Current best evidence on prescribed drugs

Pills
Drugdocs Logo

Current best evidence on prescribed drugs

Pills
HomeDrugsDRUGDOCS AIAboutNewsGlossaryContact
HomeDrugsAIAboutNewsGlossaryContact

DRUG ▾

ABCDEFGHIJKLMNOPQRSTUVWXYZ

DRUG

CLASS

AI

News

Necitumumab

(Portrazza®)

Portrazza®

Drug updated on 12/11/2024

Dosage FormInjection (intravenous; 800 mg/50 mL [16 mg/mL])
Drug ClassEpidermal growth factor receptor (EGFR) antagonists
Ongoing and
Completed Studies		ClinicalTrials.gov

Indication

  • Indicated in combination with gemcitabine and cisplatin, for first-line treatment of patients with metastatic squamous non-small cell lung cancer.

Latest News

loading GIF

Summary
This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

  • This summary is based on the review of one systematic review/meta-analysis. [1]
  • Progression-Free Survival (PFS) and Disease Control Rate (DCR): Necitumumab combined with platinum-based chemotherapy (NC) significantly improved PFS (95% CI: 0.84-0.99, P=0.03) and DCR (95% CI: 1.01-1.10, P=0.03) compared to platinum-based chemotherapy alone (CA).
  • Overall Survival (OS) and Objective Response Rate (ORR): There was no statistically significant difference in OS (95% CI: 0.85-1.01, P=0.09) or ORR (95% CI: 0.93-1.71, P=0.14) between the NC and CA groups.
  • Subgroup with High EGFR Expression: Patients with high epidermal growth factor receptor (EGFR) expression in the NC group showed a more pronounced benefit in OS compared to those in the CA group.
  • Adverse Effects in NC Group: The combination of NC was associated with a higher incidence of severe skin rash, hypomagnesemia, and venous thromboembolism compared to CA.
  • Population and Subgroup Insights: In patients with stage IV non-small cell lung cancer (NSCLC), NC demonstrated greater overall survival benefits in the subgroup with high epidermal growth factor receptor (EGFR) expression compared to the CA group.